PWE-087 Temporal change and phenotypic pattern of liver function tests can distinguish ischaemic hepatitis from drug induced liver injury– a large 6 year retrospective cohort analysis

2017 ◽  
Author(s):  
J Gulliver ◽  
H Dalton ◽  
G Aithal ◽  
H Hussaini
Keyword(s):  
Liver Injury ◽  
Liver Function ◽  
Retrospective Cohort ◽  
Temporal Change ◽  
Cohort Analysis ◽  
Liver Function Tests ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Function Tests ◽  
Retrospective Cohort Analysis

scholarly journals Case Report and Cohort Analysis of Drug-Induced Liver Injury Associated with Daptomycin

2014 ◽  
Vol 58 (8) ◽  
pp. 4902-4903 ◽  
Author(s):  
Nicole Bohm ◽  
Charles Makowski ◽  
Mario Machado ◽  
Adam Davie ◽  
Nelson Seabrook ◽  
...  
Keyword(s):  
Case Report ◽  
Liver Injury ◽  
Retrospective Cohort ◽  
Cohort Analysis ◽  
Single Center ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Retrospective Cohort Analysis ◽  
Creatinine Kinase Level

ABSTRACTA patient receiving daptomycin developed asymptomatic transaminitis and hyperbilirubinemia without concurrent multiorgan dysfunction or elevation of his creatinine kinase level. After ruling out other etiologies, the liver injury was attributed to daptomycin and was subsequently resolved. A single-center retrospective cohort analysis of baseline and follow-up liver function panels (n= 614) from all admissions from 2008 to 2013 during which daptomycin was administered did not reveal any other cases of probable or definite drug-induced liver injury associated with daptomycin.

scholarly journals Cholangiolytic Changes in Statin-Induced Liver Injury

2020 ◽  
Vol 2020 ◽  
pp. 1-4
Author(s):  
Preethi Dileep Menon ◽  
Tamneet Singh ◽  
Hopethe Hubbard ◽  
Sarah Hackman ◽  
Francis E. Sharkey
Keyword(s):  
Liver Injury ◽  
Liver Function ◽  
Biliary Tree ◽  
Liver Function Tests ◽  
Ampulla Of Vater ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Function Tests ◽  
Atorvastatin Therapy ◽  
Mixed Pattern

Atorvastatin is a commonly used oral cholesterol-lowering agent. Side effects associated with statin therapy include arthralgia, myalgia, dyspepsia, weakness, and headache. Prospective and retrospective studies of drug-induced liver injury have identified statin-induced hepatotoxicity, with atorvastatin being the most commonly cited. Associated liver function test elevations have varied from hepatocellular to cholestatic/mixed pattern. We report a case of a 58-year-old woman that illustrates unusual histologic findings associated with a mixed pattern of statin-induced liver injury. While being treated with atorvastatin, the patient exhibited repeated bouts of abdominal pain over a year associated with biliary tree dilation, variably attributed to postcholecystectomy dilation and stenosis of the ampulla of Vater. Following sphincterotomy, the patient’s bilirubin normalized but the other liver function tests remained elevated. Liver biopsy revealed portal and lobular inflammation with cholangiolysis. The patient’s liver function tests normalized following cessation of atorvastatin therapy.

scholarly journals A Patient with Nafcillin-Associated Drug-Induced Liver Failure

2017 ◽  
Vol 11 (3) ◽  
pp. 564-568 ◽  
Author(s):  
Qin Rao ◽  
Isaiah Schuster ◽  
Talal Seoud ◽  
Kevin Zarrabi ◽  
Nirvani Goolsarran
Keyword(s):  
Liver Injury ◽  
Liver Function ◽  
Liver Failure ◽  
Acute Liver Injury ◽  
Early Recognition ◽  
Antibiotic Use ◽  
Liver Function Tests ◽  
The United States ◽  
Drug Induced ◽  
Drug Induced Liver Injury

Nafcillin-induced acute liver injury is a rare and potentially fatal complication that has been known since the 1960s but inadequately studied. At this time, the only proven treatment is early discontinuation of the drug. Because of the high prevalence of nafcillin class antibiotic use in the United States, it is important for clinicians to have a high clinical suspicion for this diagnosis. We present a case of liver failure attributable to nafcillin use in a 68-year-old male with a history methicillin-sensitive Staphylococcus and L3/L4 osteomyelitis. After starting long-term antibiotic therapy, he presented with painless jaundice which necessitated discontinuation of the drug. At the time of presentation, the patient’s lab work exhibited a bilirubin/direct bilirubin of 9.4/8.2 mg/dL, alkaline phosphatase of 311 IU/L, and aspartate transaminase/alanine transaminase of 109/127 IU/L. The patient was switched to i.v. vancomycin given the concern for drug-induced liver injury. Imaging did not show obstruction of the hepatobiliary or pancreaticobiliary trees. Serology was unremarkable for viral etiology, autoimmune processes, Wilson disease, and hemochromatosis. A liver biopsy showed findings consistent with drug-induced liver injury. The patient’s liver function tests peaked at day 7 of admission and trended towards normal levels with cessation of nafcillin therapy. The patient was discharged with a diagnosis of nafcillin-induced acute liver injury. Our case highlights the importance of early recognition of the diagnosis and careful monitoring of liver function when nafcillin is employed in the clinical setting.

scholarly journals Tocilizumab and liver injury in patients with COVID-19

2020 ◽  
Vol 13 ◽  
pp. 175628482095918 ◽  
Author(s):  
Gaetano Serviddio ◽  
Rosanna Villani ◽  
Giovanni Stallone ◽  
Giulia Scioscia ◽  
Maria Pia Foschino-Barbaro ◽  
...  
Keyword(s):  
Liver Injury ◽  
Liver Function ◽  
Signal Transduction Pathway ◽  
Liver Function Tests ◽  
Drug Induced ◽  
Hypoxemic Respiratory Failure ◽  
Acute Hypoxemic Respiratory Failure ◽  
Function Tests ◽  
Elevated Liver Enzymes ◽  
The Impact

Current mortality rate in patients with COVID-19 disease is about 2%, whereas 5% of patients require admission to the intensive care unit. It is assumed that interleukin (IL)-6 may be involved in the pathogenesis of severe COVID-19 infections; therefore, in the absence of a specific antiviral therapy, some authors have suggested that tocilizumab – a drug used to block the signal transduction pathway of IL-6 – could have beneficial effects in the management of severe COVID-19 disease. However, mild-to-moderate elevation in transaminases and drug-induced liver injury have been observed in patients treated with tocilizumab. We present seven cases of patients with elevated liver enzymes [up to five times the upper limit of normal (ULN)] at baseline who received tocilizumab for life-threatening COVID-19 disease. All patients had no history of liver or pulmonary disease and were admitted for acute hypoxemic respiratory failure, dyspnea and fever due to COVID-19 bilateral pneumonia. IL-6 was available in six patients, and was significantly increased particularly in those with severe impairment of lung function. All patients received tocilizumab (8 mg/kg/day) for two consecutive days because of lack of improvement after hydroxychloroquine, azithromycin and lopinavir/ritonavir treatment. After tocilizumab administration, clinical condition rapidly improved and liver function test normalized within 3 weeks of treatment. Tocilizumab may be effective for the treatment of severe COVID-19 disease, even in patients with elevated liver function tests. Further studies are needed to evaluate the impact of tocilizumab use on liver function tests in patients with pre-existing chronic liver disease.

scholarly journals A Case Report on Drug-induced Liver Injury Induced by Antilipidemic Agents

2021 ◽  
Vol 42 (5) ◽  
pp. 777-783
Author(s):  
Seo-hye Oh ◽  
Gi-hyeon Gwon ◽  
Eun-su Park ◽  
Won-young Kim ◽  
Dong-young Kim
Keyword(s):  
Case Report ◽  
Herbal Medicine ◽  
Liver Injury ◽  
Liver Function ◽  
Total Cholesterol ◽  
Effective Treatment ◽  
Treatment Effect ◽  
Liver Function Tests ◽  
Drug Induced ◽  
Drug Induced Liver Injury

Objective: This case report describes a patient who suffered a drug-induced liver injury and was treated with Saengganggeonbi-tang.Methods: A patient was treated with Korean herbal medicine, and the treatment effect was evaluated using liver function tests (LFT) to determine total cholesterol and triglyceride levels.Results: The patient’s LFT levels were normal on 27 July 2021 but became abnormal by 12 August 2021 after taking Western drugs. After 15 days of treatment with Saengganggeonbi-tang, the LFT levels had improved.Conclusion: This study shows that Saenggangeonbi-tang may be an effective treatment for drug-induced liver injury.

scholarly journals Prophylactic Therapy of Silymarin (Milk Thistle) on Antituberculosis Drug-Induced Liver Injury: A Meta-Analysis of Randomized Controlled Trials

2019 ◽  
Vol 2019 ◽  
pp. 1-11 ◽  
Author(s):  
Lina Tao ◽  
Xiaoyu Qu ◽  
Yue Zhang ◽  
Yanqing Song ◽  
Si-xi Zhang
Keyword(s):  
Liver Injury ◽  
Liver Function ◽  
Randomized Controlled Trials ◽  
Controlled Trials ◽  
Cochrane Central Register ◽  
Prophylactic Therapy ◽  
Antituberculosis Drug ◽  
Drug Induced ◽  
Drug Induced Liver Injury ◽  
Randomized Controlled

Background. Prophylactic therapy with silymarin to prevent the development of antituberculosis drug-induced liver injury (anti-TB DILI) has been under debate. We aimed to evaluate the effect of silymarin in the prevention of anti-TB DILI. Methods. We searched MEDLINE, PubMed, Embase, and Cochrane Central Register of Controlled Trials (CENTRAL) up to 30th November 2018. Randomized controlled trials (RCTs) that compared silymarin and placebo to prevent anti-TB DILI were included. All statistical analyses were conducted using STATA 12.0 software. Standardized mean difference (SMD) and risk ratio (RR) with 95% confidence intervals (CIs) were used to evaluate the effect of silymarin. The quality of included studies was assessed according to Cochrane handbook. Funnel plots and Egger’s tests were carried out to evaluate publication bias. Sensitivity analysis was conducted to assess the influence of each study. Results. A total of 1198 patients from five RCTs (585 with silymarin and 613 with placebo groups) were included. Overall, silymarin significantly reduced the occurrence of anti-TB DILI at week 4 [RR: 0.33, 95% CI (0.15, 0.75)]. In addition, silymarin exerted protective effect on liver function in patients undergoing anti-TB drugs [SMD = − 0.15, 95% CI (−0.24, −0.07), P < 0.001 (ALT); SMD =−0.14, 95% CI (−0.23, −0.06), P = 0.001(AST); SMD =−0.12, 95% CI (−0.20, −0.03), P = 0.008 (ALP)]. Silymarin led to similar AEs in placebo groups [OR: 1.09, 95% CI (0.86, 1.39), P = 0.47]. Conclusion. Prophylactic therapy of silymarin is contributed to a noticeably reduced risk of development of anti-TB DILI four weeks after the initiation. In addition, silymarin significantly improved the liver function in patients who are receiving anti-TB drugs.

scholarly journals Methimazole induced hepatotoxicity: A rare adverse reaction

2019 ◽  
Vol 6 (3) ◽  
pp. 1
Author(s):  
Kevin C. Kohm ◽  
Lauren Pioppo ◽  
Jack Xu ◽  
Preston Keiffer ◽  
Eric Pagan ◽  
...  
Keyword(s):  
Liver Injury ◽  
Liver Function ◽  
Side Effect ◽  
Hepatic Injury ◽  
Total Bilirubin ◽  
Liver Function Tests ◽  
Side Effect Profile ◽  
Function Tests ◽  
Painless Jaundice ◽  
Graves Orbitopathy

Methimazole (MMI) is a commonly used medication in the treatment of hyperthyroidism. The side effect profile is extensive and includes the rare but serious side effect of drug associated liver injury. We report the case of a 51-year-old female who presented with painless jaundice several weeks after initiating MMI therapy for treatment of hyperthyroidism complicated by Graves’ orbitopathy. Liver function tests on presentation showed alanine aminotransferase (ALT) 1366 IU/L, aspartate aminotransferase (AST) 853 IU/L, total bilirubin 26.2 mg/dl, alkaline phosphatase 954 IU/L. Workup of structural, infectious, and autoimmune causes of hepatic injury was negative. The patient was therefore found to have MMI associated liver injury. MMI was discontinued and the patient was started on ursodiol, resulting in resolution of her jaundice and improvement of her liver function tests.

Sign in / Sign up

Export Citation Format

Share Document